Janssen W E, Farmelo M J, Lee C, Smilee R, Kronish L, Elfenbein G J
Department of Internal Medicine, University of South Florida, Tampa 33612.
Exp Hematol. 1992 May;20(4):528-30.
We have measured the presence of granulocyte-macrophage colony forming cells (CFU-GM) and CD34+ cells in blood and bone marrow. We have compared these hematopoietic cell assays using regression analysis. We have found that under the limited and specific case of blood cells from an individual recovering from myelo-suppressive chemotherapy, the fraction of cells that is CD34 positive is predictive of the number of granulocyte-macrophage colonies (CFU-GM) which will grow. This result is in agreement with published data. We have found, however, that in bone marrow aspirates, or in the blood of individuals recovering from cyclophosphamide chemotherapy and receiving either granulocyte-macrophage colony stimulating factor (G-CSF) or folinic acid (FA) therapy, there is poor correlation between CD34+ cell fraction and CFU-GM. Accordingly, the use of CD34+ fraction cannot be relied upon to substitute for the CFU-GM assay in assessing the hematopoietic cell content of blood or bone marrow samples.
我们已经检测了血液和骨髓中粒细胞-巨噬细胞集落形成细胞(CFU-GM)和CD34+细胞的存在情况。我们使用回归分析比较了这些造血细胞检测方法。我们发现,在接受骨髓抑制化疗后正在恢复的个体的血细胞这一有限且特定的情况下,CD34阳性细胞的比例可预测将会生长的粒细胞-巨噬细胞集落(CFU-GM)的数量。这一结果与已发表的数据一致。然而,我们发现,在骨髓穿刺液中,或在接受环磷酰胺化疗后正在恢复且接受粒细胞-巨噬细胞集落刺激因子(G-CSF)或亚叶酸(FA)治疗的个体的血液中,CD34+细胞比例与CFU-GM之间的相关性较差。因此,在评估血液或骨髓样本的造血细胞含量时,不能依靠CD34+比例来替代CFU-GM检测。